In type 1 diabetes, insulin-making cells may not only be attacked by the immune system—they may also be destroyed by a chain reaction involving iron and damaged fats. Blocking that reaction helped preserve signs of pancreatic health in diabetic mice.

The loss of insulin-making cells is the most important damaging feature of both type 1 and type 2 diabetes, and cell death is considered its main cause. Imagine a pan of cooking oil left on high heat: it begins to break down and spread damage.

In these cells, iron-dependent damage to fats may create a similarly destructive chain reaction called ferroptosis. Insulin-making cells have low antioxidant capacity, so they are especially vulnerable to this kind of damage. The study set out to understand how insulin-making cells are lost under diabetic conditions, including whether they show the pattern expected from ferroptosis.

It also tested whether blocking ferroptosis could benefit the hormone-producing part of the pancreas under diabetic conditions. In diabetic animals, blood glucose and insulin levels were significantly altered. When the ferroptosis blocker was given at the same time, blood glucose moved slightly toward the control level, while insulin rose above the untreated diabetic group.

The pancreas showed a matching pattern: the insulin-producing clusters shrank less in treated diabetic animals than in untreated diabetic animals. The scar-like material around and inside those clusters also tended to move toward the control level with treatment.

Diabetes leaves pancreatic islet cells with more broken DNA, fat-related damage, waste buildup, and iron-filled scavenger cells. Fer-1 treatment reduces these signs, pointing to a connected form of cell injury rather than isolated damage. In diabetic animals, Nrf two immunopositivity in islet cells decreased, while Fer one sharply increased it beyond control levels, including more Nrf two-positive nuclei.

The treatment sharply increased Nrf2, including more Nrf2-positive nuclei, showing that the protection program was more active after the ferroptosis blocker was given. The same pattern appeared for GPX4: treated diabetic tissue had strong levels throughout the hormone-producing tissue, unlike the weaker pattern in control and diabetic tissue.

Taken together, lower Nrf2 and several of its protective targets, followed by an accumulation of damaged fats in the insulin-producing cells, suggest that ferroptosis is an important way these cells are removed in type 1 diabetes. The study also links reduced PRDX-2 to ferroptosis in these cells, adding another part to the damage pattern.

The picture ties diabetes-related loss of insulin-making cells to a chain of damage ending in ferroptosis, a form of cell death driven by fat damage. It also summarizes how ferrostatin-1 interrupts that chain by restoring the cells’ protective response and reducing tissue injury.

The study suggests that this iron-linked cell death contributes importantly to type 1 diabetes, and that stopping it could become a way to protect insulin-making cells and improve diabetes treatment.